Aura Biosciences notices resale of 37,500 RSU shares
Aura Biosciences, Inc. reports a proposed sale of 37,500 shares of Common Stock represented by a restricted stock unit award granted under the company's 2021 Stock Option and Incentive Plan.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Aura Biosciences, Inc. reports a proposed sale of 37,500 shares of Common Stock represented by a restricted stock unit award granted under the company's 2021 Stock Option and Incentive Plan. The RSU award is dated 06/02/2025 and the Form 144 filing entry is dated 06/16/2026.
The entry lists the securities to be sold as Common Stock on Nasdaq and identifies the award as subject to vesting requirements under the 2021 plan.
Insights
Form 144 notifies the SEC of a proposed resale of restricted shares.
The entry shows 37,500 shares tied to an RSU grant under the 2021 Stock Option and Incentive Plan, dated 06/02/2025. Form 144 is a notice of intent to sell under Rule 144; it does not itself effect a sale.
Cash‑flow treatment and whether the RSUs have satisfied vesting conditions are not stated in the excerpt; subsequent filings or broker records would show completed transactions.
Key Figures
Key Terms
Restricted Stock Unit (RSU) financial
Form 144 regulatory
2021 Stock Option and Incentive Plan financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Aura Biosciences' Form 144 for AURA report?
AI-generated analysis. How Rhea-AI works. Not financial advice.